 |
|
|
|
 |
|||
Dressing impossibly cute kids in equally cute clothes is a big business, as evidenced by private investment firm Bain Capital’s agreement to buy Gymboree (GYMB) for $65.40 per share. The $1.8 billion offer price includes a premium of about 22 percent over Gymboree’s closing price on the day before the deal was announced. Offering a premium, [...]
A lot of companies are jumping into M&A deals willingly, but that’s certainly not the case for Genzyme Corporation (GENZ), which is doing its best to fend off Sanofi-Aventis SA’s (SNY) $18.5 billion hostile takeover proposal – despite the buckets of cash that Genzyme’s executives would get in the process. On October 7, Genzyme issued a [...]
We’re spending part of the next two days at the (warning: mute your computers before clicking) Value Investing Congress at the Marriott Marquis in Times Square listening to a bunch of mostly value-oriented managers talk about the secrets to their success. Among those slated to speak today are David Einhorn, Joel Greenblatt and Julian Robertson. [...]
Keeping up with what’s going on with Midas (MDS) these past few days in terms of SEC filings takes something of a scorecard. Last week, the company announced that its’ annual report — due last Thursday — would be late. And then a British investor who owns just over 8% of Midas stock filed this [...]
Earlier this week, Barrington Capital and Newcastle Partners sent this letter to Dillard’s (DDS) asking to inspect the company’s records and books, including board minutes, corporate jet records and records related to transactions with various members of the Dillard family. The letter was virtually identical to this one sent back in March. While the story [...]
